UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2023
Commission File Number:
(Translation of registrant’s name into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jerusalem, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Explanatory Note
This Amendment No. 1 to the Report on Form 6-K, originally filed with the Securities and Exchange Commission on August 11, 2023, is being filed solely for the purposes of furnishing unaudited interim condensed consolidated financial statements as of June 30, 2023, and incorporating certain exhibits into registration statements of the registrant.
This Report on Form 6-K (including the text under “Second Quarter 2022 Financial Summary” in Exhibit 99.1, and Exhibit 99.2) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344), Form F-1 (File No. 333-267648) and Form F-3 (File No. 333-240189), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
| Exhibit No. | Description | |
| 99.1 | Press Release, dated August 11, 2023. | |
| 99.2 | Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2023. |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BiondVax Pharmaceuticals Ltd. | ||
| By: | /s/ Amir Reichman | |
| Amir Reichman | ||
| Chief Executive Officer | ||
August 14, 2023
2